$JNJ (-1,01 %) | Johnson & Johnson Q3'24 Earnings Highlights:

🔹 Adj EPS: $2.42 (Est. $2.19) 🟢; DOWN -9.0% YoY

🔹 Sales: $22.47B (Est. $22.16B) 🟢; UP +5.2% YoY

🔹 Net Income: $2.69B; DOWN -37.5% YoY

FY'24 Guidance:

🔹 Raises Operational Sales Guidance to $89.4B - $89.8B (SAW: $89.2B - $89.6B) 😐

🔹 Lowers Adjusted Operational EPS Guidance to $9.86 - $9.96 (SAW: $10.00 - $10.10) 😐

Segment:

🔸Innovative Medicine Sales: $14.58B; UP +4.9% YoY

— Driven by key brands: DARZALEX, ERLEADA, TREMFYA, SPRAVATO

🔹 Oncology Drug Sales: UP +19% YoY

🔹 DARZALEX Revenue: $3.02B; UP +20.7% YoY

🔹 CARVYKTI Sales: $286M (Est. $239M) 🟢

🔹 STELARA Sales: $2.68B; DOWN -6.6% YoY, but beat estimates

🔸MedTech Sales: $7.89B (Est. $8.05B) 🔴; UP +5.8% YoY

— Growth driven by electrophysiology products, Abiomed, and contact lenses

— Faced headwinds in Asia Pacific, including China and Japan

CEO Joaquin Duato's Commentary:

🔸 "Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation."

Additional Highlights:

🔸 Oncology segment growth propelled by 11 assets delivering double-digit growth

🔸 Company working to boost CARVYKTI production capacity

🔸 TREMFYA received FDA approval for ulcerative colitis

🔸 MedTech business delivered operational sales growth of 6.4%, including the addition of Shockwave Medical